Elevation Oncology （ELEV）

All in ELEV 57,000 shares @ 0.67. Company currently holds $103.07 million cash against 36.95 million total liabilities. This proves the company is well positioned to fund its operation through 2026.

The stock is currently trading at its absolute bottom, with extremely low volume, indicating a potential undervaluation. Just one piece of positive news (contract, partnership, operation milestone), stock price could easily go above $1.

While six wall street analysts have set an average price target of $7.2, I doubt this would happen unless they have very strong catalyst.

That said, without even hitting the $7.2 target price, the stock have substantial room to grow. Just one piece of positive new could easily push the price above $1.

FYI: Do your own research and this is not financial advice.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elev/elevation-oncology/health

https://www.marketbeat.com/stocks/NASDAQ/ELEV/forecast/#google_vignette